Status of hepatitis C virus vaccination: Recent update

World Journal of Gastroenterology

Volumn 22, Issue 2, 2016, Pages 862-873

  Abdelwahab, Kouka Saadeldin ^a   Said, Zeinab Nabil Ahmed ^a  

^a AL AZHAR UNIVERSITY   (Egypt)

Author keywords

Clinical trials; Hepatitis C; Hepatitis C virus vaccine; Immune response; Viral envelope glycoproteins

Indexed keywords

DNA VACCINE; HEPATITIS C VACCINE; PEPTIDE VACCINE; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; SYNTHETIC PEPTIDE; VIRUS VECTOR; HEPATITIS VACCINE;

ADAPTIVE IMMUNITY; ANTIBODY MEDIATED IMMUNE RESPONSE; ANTIBODY RESPONSE; ANTIVIRAL THERAPY; CELLULAR IMMUNITY; DENDRITIC CELL; DOWN REGULATION; GENETIC VARIABILITY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INNATE IMMUNITY; LIVER CELL; META ANALYSIS (TOPIC); MOLECULAR INTERACTION; MOLECULAR WEIGHT; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; TH1 CELL; VACCINATION; VACCINE PRODUCTION; VIRAL CLEARANCE; VIRUS ATTACHMENT; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS LIKE AGENT; VIRUS LOAD; VIRUS PARTICLE; VIRUS REPLICATION; ANIMAL; GENETICS; HEPATITIS VIRUS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; PATHOGENICITY; TREATMENT OUTCOME;

ANIMALS; GENOTYPE; HEPATITIS C; HEPATITIS VIRUSES; HOST-PATHOGEN INTERACTIONS; HUMANS; TREATMENT OUTCOME; VIRAL HEPATITIS VACCINES;

EID: 84954436919     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i2.862     Document Type: Review

References (104)

1. Stoll-Keller F, Barth H, Fafi-Kremer S, Zeisel MB, Baumert TF. Development of hepatitis C virus vaccines: challenges and progress. Expert Rev Vaccines 2009; 8: 333-345 [PMID: 19249975 DOI: 10.1586/14760584.8.3.333]
2. Lindenbach BD, Thiel HJ, Rice CM. Flaviviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Fields Virology. 5th ed. Philadelphia: Lippincott-Raven Publishers, 2007: 1101-1152
3. Kong L, Giang E, Nieusma T, Kadam RU, Cogburn KE, Hua Y, Dai X, Stanfeld RL, Burton DR, Ward AB, Wilson IA, Law M. Hepatitis C virus E2 envelope glycoprotein core structure. Science 2013; 342: 1090-1094 [PMID: 24288331]
4. Wang Y, Keck ZY, Foung SK. Neutralizing antibody response to hepatitis C virus. Viruses 2011; 3: 2127-2145 [PMID: 22163337 DOI: 10.3390/v3112127]
5. Pishraft Sabet L, Taheri T, Memarnejadian A, Mokhtari Azad T, Asgari F, Rahimnia R, Alavian SM, Rafati S, Samimi Rad K. Immunogenicity of Multi-Epitope DNA and Peptide Vaccine Candidates Based on Core, E2, NS3 and NS5B HCV Epitopes in BALB/c Mice. Hepat Mon 2014; 14: e22215 [PMID: 25419219 DOI: 10.5812/hepatmon.22215]
6. Edlin BR. Perspective: test and treat this silent killer. Nature 2011; 474: S18-S19 [PMID: 21613999 DOI: 10.1038/474S18a]
7. Dahari H, Feinstone SM, Major ME. Meta-analysis of hepatitis C virus vaccine effcacy in chimpanzees indicates an importance for structural proteins. Gastroenterology 2010; 139: 965-974 [PMID: 20621699 DOI: 10.1053/j.gastro.2010.05.077]
8. Colombatto P, Brunetto MR, Maina AM, Romagnoli V, Almasio P, Rumi MG, Ascione A, Pinzello G, Mondelli M, Muratori L, Rappuoli R, Rosa D, Houghton M, Abrignani S, Bonino F. HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFNα2a and Ribavirin: a randomized controlled trial. J Viral Hepat 2014; 21: 458-465 [PMID: 24750327 DOI: 10.1111/jvh.12163]
9. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, Perelson AS. Hepatitis C viral dynamics in vivo and the antiviral effcacy of interferon-alpha therapy. Science 1998; 282: 103-107 [PMID: 9756471]
10. Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 2004; 85: 3173-3188 [PMID: 15483230]
11. Stumpf MP, Pybus OG. Genetic diversity and models of viral evolution for the hepatitis C virus. FEMS Microbiol Lett 2002; 214: 143-152 [PMID: 12351222]
12. Duffy S, Shackelton LA, Holmes EC. Rates of evolutionary change in viruses: patterns and determinants. Nat Rev Genet 2008; 9: 267-276 [PMID: 18319742]
13. Cashman SB, Marsden BD, Dustin LB. The Humoral Immune Response to HCV: Understanding is Key to Vaccine Development. Front Immunol 2014; 5: 550 [PMID: 25426115 DOI: 10.3389/fmmu.2014.00550]
14. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014; 59: 318-327 [PMID: 24115039]
15. Forns X, Thimme R, Govindarajan S, Emerson SU, Purcell RH, Chisari FV, Bukh J. Hepatitis C virus lacking the hypervariable region 1 of the second envelope protein is infectious and causes acute resolving or persistent infection in chimpanzees. Proc Natl Acad Sci USA 2000; 97: 13318-13323 [PMID: 11078521]
16. Prentoe J, Jensen TB, Meuleman P, Serre SB, Scheel TK, Leroux-Roels G, Gottwein JM, Bukh J. Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. J Virol 2011; 85: 2224-2234 [PMID: 21123377]
17. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R, Vitelli A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J 2002; 21: 5017-5025 [PMID: 12356718]
18. Brimacombe CL, Grove J, Meredith LW, Hu K, Syder AJ, Flores M V, Timpe JM, Krieger SE, Baumert TF, Tellinghuisen TL, Wong-Staal F, Balfe P, McKeating JA. Neutralizing antibody-resistant hepatitis C virus cell-to-cell transmission. J Virol 2011; 85: 596-605 [PMID: 20962076 DOI: 10.1128/JVI.01592-10]
19. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 2009; 457: 882-886 [PMID: 19182773]
20. Jeulin H, Velay A, Murray J, Schvoerer E. Clinical impact of hepatitis B and C virus envelope glycoproteins. World J Gastroenterol 2013; 19: 654-664 [PMID: 23429668 DOI: 10.3748/wjg.v19.i5.654]
21. Martin DN, Uprichard SL. Identifcation of transferrin receptor 1 as a hepatitis C virus entry factor. Proc Natl Acad Sci USA 2013; 110: 10777-10782 [PMID: 23754414 DOI: 10.1073/pnas.1301764110]
22. Verma R, Khanna P, Chawla S. Hepatitis C vaccine. Need of the hour. Hum Vaccin Immunother 2014; 10: 1927-1929 [PMID: 25424801 DOI: 10.4161/hv.29033]
23. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following acute hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006; 13: 34-41 [PMID: 16364080]
24. Hajarizadeh B, Grebely J, Dore GJ. Epidemiology and natural history of HCV infection. Nat Rev Gastroenterol Hepatol 2013; 10: 553-562 [PMID: 23817321]
25. Chmielewska AM, Naddeo M, Capone S, Ammendola V, Hu K, Meredith L, Verhoye L, Rychlowska M, Rappuoli R, Ulmer JB, Colloca S, Nicosia A, Cortese R, Leroux-Roels G, Balfe P, Bienkowska-Szewczyk K, Meuleman P, McKeating JA, Folgori A. Combined adenovirus vector and hepatitis C virus envelope protein prime-boost regimen elicits T cell and neutralizing antibody immune responses. J Virol 2014; 88: 5502-5510 [PMID: 24599994 DOI: 10.1128/JVI.03574-13]
26. WHO factsheet: HCV vaccines, number 164. Accessed February 27, 2015. Available from: URL: http://www.who.int/mediacentre/factsheets/fs164/en/
27. Zingaretti C, De Francesco R, Abrignani S. Why is it so diffcult to develop a hepatitis C virus preventive vaccine? Clin Microbiol Infect 2014; 20 Suppl 5: 103-109 [PMID: 24829939]
28. Latimer B, Toporovski R, Yan J, Pankhong P, Morrow MP, Khan AS, Sardesai NY, Welles SL, Jacobson JM, Weiner DB, Kutzler MA. Strong HCV NS3/4a, NS4b, NS5a, NS5b-specific cellular immune responses induced in Rhesus macaques by a novel HCV genotype 1a/1b consensus DNA vaccine. Hum Vaccin Immunother 2014; 10: 2357-2365 [PMID: 25424943 DOI: 10.4161/hv.29590]
29. Ippolito G, Capobianchi MR, Lanini S, Antonelli G. Is hepatitis C virus eradication around the corner only 25 years after its discovery? Int J Antimicrob Agents 2015; 45: 111-112 [PMID: 25249016 DOI: 10.1016/j.ijantimicag.2014.09.001]
30. Torresi J, Johnson D, Wedemeyer H. Progress in the development of preventive and therapeutic vaccines for hepatitis C virus. J Hepatol 2011; 54: 1273-1285 [PMID: 21236312 DOI: 10.1016/j.jhep.2010.09.040]
31. Mailly L, Robinet E, Meuleman P, Baumert TF, Zeisel MB. Hepatitis C virus infection and related liver disease: the quest for the best animal model. Front Microbiol 2013; 4: 213 [PMID: 23898329 DOI: 10.3389/fmicb.2013.00212]
32. Ball JK, Tarr AW, McKeating JA. The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res 2014; 105: 100-111 [PMID: 24583033 DOI: 10.1016/j.antiviral.2014.02.013]
33. Dustin LB, Cashman SB, Laidlaw SM. Immune control and failure in HCV infection-tipping the balance. J Leukoc Biol 2014; 96: 535-548 [PMID: 25015956 DOI: 10.1189/jlb.4RI0214-126R]
34. Irshad M, Khushboo I, Singh S, Singh S. Hepatitis C virus (HCV): a review of immunological aspects. Int Rev Immunol 2008; 27: 497-517 [PMID: 19065353 DOI: 10.1080/08830180802432178]
35. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009; 119: 1745-1754 [PMID: 19587449 DOI: 10.1172/JCI39133]
36. Rehermann B. Pathogenesis of chronic viral hepatitis: differential roles of T cells and NK cells. Nat Med 2013; 19: 859-868 [PMID: 23836236 DOI: 10.1038/nm.3251]
37. Neumann-Haefelin C, Thimme R. Adaptive immune responses in hepatitis C virus infection. Curr Top Microbiol Immunol 2013; 369: 243-262 [PMID: 23463204 DOI: 10.1007/978-3-642-27340-7-10]
38. Shoukry NH, Grakoui A, Houghton M, Chien DY, Ghrayeb J, Reimann KA, Walker CM. Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med 2003; 197: 1645-1655 [PMID: 12810686]
39. Park SH, Rehermann B. Immune responses to HCV and other hepatitis viruses. Immunity 2014; 40: 13-24 [PMID: 24439265 DOI: 10.1016/j.immuni.2013.12.010]
40. Osburn WO, Fisher BE, Dowd KA, Urban G, Liu L, Ray SC, Thomas DL, Cox AL. Spontaneous control of primary hepatitis C virus infection and immunity against persistent reinfection. Gastroenterology 2010; 138: 315-324 [PMID: 19782080 DOI: 10.1053/j.gastro.2009.09.017]
41. Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, Rice CM, Ploss A, Burton DR, Law M. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci USA 2012; 109: 6205-6210 [PMID: 22492964 DOI: 10.1073/pnas.1114927109]
42. Osburn WO, Snider AE, Wells BL, Latanich R, Bailey JR, Thomas DL, Cox AL, Ray SC. Clearance of hepatitis C infection is associated with the early appearance of broad neutralizing antibody responses. Hepatology 2014; 59: 2140-2151 [PMID: 24425349 DOI: 10.1002/hep.27013]
43. Shimizu YK, Hijikata M, Iwamoto A, Alter HJ, Purcell RH, Yoshikura H. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. J Virol 1994; 68: 1494-1500 [PMID: 8107212]
44. Pestka JM, Zeisel MB, Bläser E, Schürmann P, Bartosch B, Cosset FL, Patel AH, Meisel H, Baumert J, Viazov S, Rispeter K, Blum HE, Roggendorf M, Baumert TF. Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C. Proc Natl Acad Sci USA 2007; 104: 6025-6030 [PMID: 17392433]
45. Perotti M, Mancini N, Diotti RA, Tarr AW, Ball JK, Owsianka A, Adair R, Patel AH, Clementi M, Burioni R. Identification of a broadly cross-reacting and neutralizing human monoclonal antibody directed against the hepatitis C virus E2 protein. J Virol 2008; 82: 1047-1052 [PMID: 17989176]
46. Haberstroh A, Schnober EK, Zeisel MB, Carolla P, Barth H, Blum HE, Cosset FL, Koutsoudakis G, Bartenschlager R, Union A, Depla E, Owsianka A, Patel AH, Schuster C, Stoll-Keller F, Doffoël M, Dreux M, Baumert TF. Neutralizing host responses in hepatitis C virus infection target viral entry at postbinding steps and membrane fusion. Gastroenterology 2008; 135: 1719-1728.e1 [PMID: 18718838]
47. Morin TJ, Broering TJ, Leav BA, Blair BM, Rowley KJ, Boucher EN, Wang Y, Cheslock PS, Knauber M, Olsen DB, Ludmerer SW, Szabo G, Finberg RW, Purcell RH, Lanford RE, Ambrosino DM, Molrine DC, Babcock GJ. Human monoclonal antibody HCV1 effectively prevents and treats HCV infection in chimpanzees. PLoS Pathog 2012; 8: e1002895 [PMID: 22952447]
48. Law M, Maruyama T, Lewis J, Giang E, Tarr AW, Stamataki Z, Gastaminza P, Chisari F V, Jones IM, Fox RI, Ball JK, McKeating JA, Kneteman NM, Burton DR. Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge. Nat Med 2008; 14: 25-27 [PMID: 18064037]
49. Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, Rehermann B. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis 2012; 205: 763-771 [PMID: 22293431]
50. von Hahn T, Yoon JC, Alter H, Rice CM, Rehermann B, Balfe P, McKeating JA. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. Gastroenterology 2007; 132: 667-678 [PMID: 17258731]
51. Helle F, Goffard A, Morel V, Duverlie G, McKeating J, Keck Z Y, Foung S, Penin F, Dubuisson J, Voisset C. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specifc glycans on the E2 envelope protein. J Virol 2007; 81: 8101-8111 [PMID: 17522218]
52. Nielsen SU, Bassendine MF, Burt AD, Martin C, Pumeechockchai W, Toms GL. Association between hepatitis C virus and very-low-density lipoprotein (VLDL)/LDL analyzed in iodixanol density gradients. J Virol 2006; 80: 2418-2428 [PMID: 16474148]
53. Zhang P, Wu CG, Mihalik K, Virata-Theimer ML, Yu M Y, Alter HJ, Feinstone SM. Hepatitis C virus epitope-specifc neutralizing antibodies in Igs prepared from human plasma. Proc Natl Acad Sci USA 2007; 104: 8449-8454 [PMID: 17494735]
54. Dreux M, Cosset FL. The scavenger receptor BI and its ligand, HDL: partners in crime against HCV neutralizing antibodies. J Viral Hepat 2007; 14 Suppl 1: 68-76 [PMID: 17958646]
55. Timpe JM, Stamataki Z, Jennings A, Hu K, Farquhar MJ, Harris HJ, Schwarz A, Desombere I, Roels GL, Balfe P, McKeating JA. Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies. Hepatology 2008; 47: 17-24 [PMID: 17941058]
56. Witteveldt J, Evans MJ, Bitzegeio J, Koutsoudakis G, Owsianka AM, Angus AG, Keck ZY, Foung SK, Pietschmann T, Rice CM, Patel AH. CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells. J Gen Virol 2009; 90: 48-58 [PMID: 19088272]
57. Tarr AW, Lafaye P, Meredith L, Damier-Piolle L, Urbanowicz RA, Meola A, Jestin JL, Brown RJ, McKeating JA, Rey FA, Ball JK, Krey T. An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission. Hepatology 2013; 58: 932-939 [PMID: 23553604]
58. Mazumdar B, Kim H, Meyer K, Bose SK, Di Bisceglie AM, Ray RB, Ray R. Hepatitis C virus proteins inhibit C3 complement production. J Virol 2012; 86: 2221-2228 [PMID: 22171262]
59. Kim H, Meyer K, Di Bisceglie AM, Ray R. Hepatitis C virus suppresses C9 complement synthesis and impairs membrane attack complex function. J Virol 2013; 87: 5858-5867 [PMID: 23487461]
60. Mazumdar B, Kim H, Meyer K, Bose SK, Di Bisceglie AM, Ray RB, Diamond MS, Atkinson JP, Ray R. Hepatitis C virus infection upregulates CD55 expression on the hepatocyte surface and promotes association with virus particles. J Virol 2013; 87: 7902-7910 [PMID: 23658447]
61. Swadling L, Klenerman P, Barnes E. Ever closer to a prophylactic vaccine for HCV. Expert Opin Biol Ther 2013; 13: 1109-1124 [PMID: 23651228 DOI: 10.1517/14712598.2013.791277]
62. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Kräusslich HG, Mizokami M, Bartenschlager R, Liang TJ. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-796 [PMID: 15951748]
63. Shi C, Ploss A. Hepatitis C virus vaccines in the era of new direct-acting antivirals. Expert Rev Gastroenterol Hepatol 2013; 7: 171-185 [PMID: 23363265 DOI: 10.1586/egh.12.72]
64. Bowen DG, Walker CM. Mutational escape from CD8+ T cell immunity: HCV evolution, from chimpanzees to man. J Exp Med 2005; 201: 1709-1714 [PMID: 15939787]
65. Uebelhoer L, Han JH, Callendret B, Mateu G, Shoukry NH, Hanson HL, Rice CM, Walker CM, Grakoui A. Stable cytotoxic T cell escape mutation in hepatitis C virus is linked to maintenance of viral ftness. PLoS Pathog 2008; 4: e1000143 [PMID: 18773115]
66. Huang XJ, Lü X, Lei YF, Yang J, Yao M, Lan HY, Zhang JM, Jia ZS, Yin W, Xu ZK. Cellular immunogenicity of a multi-epitope peptide vaccine candidate based on hepatitis C virus NS5A, NS4B and core proteins in HHD-2 mice. J Virol Methods 2013; 189: 47-52 [PMID: 23333413 DOI: 10.1016/j.jviromet.2013.01.003]
67. Burton DR, Poignard P, Stanfield RL, Wilson IA. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012; 337: 183-186 [PMID: 22798606]
68. Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, Part one: Advances in basic knowledge for hepatitis C virus vaccine design. Expert Opin Ther Pat 2011; 21: 1811-1830 [PMID: 22022980 DOI: 10.1517/13543776.2011.630662]
69. Garcia A, Fernandez S, Toro F, De Sanctis JB. An overview of hepatitis C vaccines. Recent Pat Inflamm Allergy Drug Discov 2014; 8: 85-91 [PMID: 25000932]
70. Roohvand F, Kossari N. Advances in hepatitis C virus vaccines, part two: advances in hepatitis C virus vaccine formulations and modalities. Expert Opin Ther Pat 2012; 22: 391-415 [PMID: 22455502 DOI: 10.1517/13543776.2012.673589]
71. Zhu W, Fu J, Lu J, Deng Y, Wang H, Wei Y, Deng L, Tan W, Liang G. Induction of humoral and cellular immune responses against hepatitis C virus by vaccination with replicon particles derived from Sindbis-like virus XJ-160. Arch Virol 2013; 158: 1013-1019 [PMID: 23250650 DOI: 10.1007/s00705-012-1564-8]
72. Qiu Q, Wang RY, Jiao X, Jin B, Sugauchi F, Grandinetti T, Alter HJ, Shih JW. Induction of multispecifc Th-1 type immune response against HCV in mice by protein immunization using CpG and Montanide ISA 720 as adjuvants. Vaccine 2008; 26: 5527-5534 [PMID: 18675871 DOI: 10.1016/j.vaccine.2008.07.034]
73. Weiland O, Ahlén G, Diepolder H, Jung MC, Levander S, Fons M, Mathiesen I, Sardesai N Y, Vahlne A, Frelin L, Sällberg M. Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C. Mol Ther 2013; 21: 1796-1805 [PMID: 23752314 DOI: 10.1038/mt.2013.119]
74. Houghton M. Prospects for prophylactic and therapeutic vaccines against the hepatitis C viruses. Immunol Rev 2011; 239: 99-108 [PMID: 21198667 DOI: 10.1111/j.1600-065X.2010.00977.x]
75. Stamataki Z, Coates S, Evans MJ, Wininger M, Crawford K, Dong C, Fong YL, Chien D, Abrignani S, Balfe P, Rice CM, McKeating JA, Houghton M. Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine 2007; 25: 7773-7784 [PMID: 17919789 DOI: 10.1016/j.vaccine.2007.08.053]
76. Meunier JC, Gottwein JM, Houghton M, Russell RS, Emerson SU, Bukh J, Purcell RH. Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus. J Infect Dis 2011; 204: 1186-1190 [PMID: 21917891 DOI: 10.1093/infdis/jir511]
77. Stamataki Z, Coates S, Abrignani S, Houghton M, McKeating JA. Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross-neutralize heterologous virus strains. J Infect Dis 2011; 204: 811-813 [PMID: 21788452 DOI: 10.1093/infdis/jir399]
78. Wong JA, Bhat R, Hockman D, Logan M, Chen C, Levin A, Frey SE, Belshe RB, Tyrrell DL, Law JL, Houghton M. Recombinant hepatitis C virus envelope glycoprotein vaccine elicits antibodies targeting multiple epitopes on the envelope glycoproteins associated with broad cross-neutralization. J Virol 2014; 88: 14278-14288 [PMID: 25275133 DOI: 10.1128/JVI.01911-14]
79. Lindenbach BD, Evans MJ, Syder AJ, Wölk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA, Rice CM. Complete replication of hepatitis C virus in cell culture. Science 2005; 309: 623-626 [PMID: 15947137]
80. Gottwein JM, Bukh J. Viral hepatitis: Cell-culture-derived HCV-A promising vaccine antigen. Nat Rev Gastroenterol Hepatol 2013; 10: 508-509 [PMID: 23897287 DOI: 10.1038/nrgastro.2013.136]
81. Akazawa D, Moriyama M, Yokokawa H, Omi N, Watanabe N, Date T, Morikawa K, Aizaki H, Ishii K, Kato T, Mochizuki H, Nakamura N, Wakita T. Neutralizing antibodies induced by cell culture-derived hepatitis C virus protect against infection in mice. Gastroenterology 2013; 145: 447-55.e1-4 [PMID: 23673355 DOI: 10.1053/j.gastro.2013.05.007]
82. Patient R, Hourioux C, Vaudin P, Pagès JC, Roingeard P. Chimeric hepatitis B and C viruses envelope proteins can form subviral particles: implications for the design of new vaccine strategies. N Biotechnol 2009; 25: 226-234 [PMID: 19356608 DOI: 10.1016/j.nbt.2009.01.001]
83. Naderi M, Gholipour N, Zolfaghari MR, Moradi Binabaj M, Yegane Moghadam A, Motalleb G. Hepatitis C virus and vaccine development. Int J Mol Cell Med 2014; 3: 207-215 [PMID: 25635247]
84. Ahlen G, Nystrom J, Pult I, Frelin L, Hultgren C, Sallberg M. In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes. J Infect Dis 2005; 192: 2112-2116 [PMID: 16288375]
85. Draper SJ, Heeney JL. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 2010; 8: 62-73 [PMID: 19966816 DOI: 10.1038/nrmicro2240]
86. Beaumont E, Roingeard P. Prospects for prophylactic hepatitis C vaccines based on virus-like particles. Hum Vaccin Immunother 2013; 9: 1112-1118 [PMID: 23406827 DOI: 10.4161/hv.23900]
87. Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, Siani L, Naddeo M, Grazioli F, Esposito ML, Ambrosio M, Sparacino A, Bartiromo M, Meola A, Smith K, Kurioka A, O' Hara GA, Ewer KJ, Anagnostou N, Bliss C, Hill AV, Traboni C, Klenerman P, Cortese R, Nicosia A. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012; 4: 115ra2 [PMID: 22218691 DOI: 10.1126/scitranslmed.3002925]
88. Garrone P, Fluckiger AC, Mangeot PE, Gauthier E, Dupeyrot-Lacas P, Mancip J, Cangialosi A, Du Chéné I, LeGrand R, Mangeot I, Lavillette D, Bellier B, Cosset FL, Tangy F, Klatzmann D, Dalba C. A prime-boost strategy using virus-like particles pseudotyped for HCV proteins triggers broadly neutralizing antibodies in macaques. Sci Transl Med 2011; 3: 94ra71 [PMID: 21813755 DOI: 10.1126/scitranslmed.3002330]
89. Yu H, Babiuk LA, van Drunen Littel-van den Hurk S. Strategies for loading dendritic cells with hepatitis C NS5a antigen and inducing protective immunity. J Viral Hepat 2008; 15: 459-470 [PMID: 18221298 DOI: 10.1111/j.1365-2893.2008.00959.x]
90. Mishra S, Lavelle BJ, Desrosiers J, Ardito MT, Terry F, Martin WD, De Groot AS, Gregory SH. Dendritic cell-mediated, DNA-based vaccination against hepatitis C induces the multi-epitope-specific response of humanized, HLA transgenic mice. PLoS One 2014; 9: e104606 [PMID: 25111185 DOI: 10.1371/journal. pone.0104606]
91. Meuleman P, Bukh J, Verhoye L, Farhoudi A, Vanwolleghem T, Wang RY, Desombere I, Alter H, Purcell RH, Leroux-Roels G. In vivo evaluation of the cross-genotype neutralizing activity of polyclonal antibodies against hepatitis C virus. Hepatology 2011; 53: 755-762 [PMID: 21319203]
92. Beaumont E, Roingeard P. Chimeric hepatitis B virus (HBV)/hepatitis C virus (HCV) subviral envelope particles induce effcient anti-HCV antibody production in animals pre-immunized with HBV vaccine. Vaccine 2015; 33: 973-976 [PMID: 25596457 DOI: 10.1016/j.vaccine.2015.01.007]
93. Young AM, Stephens DB, Khaleel HA, Havens JR. Hepatitis C vaccine clinical trials among people who use drugs: potential for participation and involvement in recruitment. Contemp Clin Trials 2015; 41: 9-16 [PMID: 25553715 DOI: 10.1016/j.cct.2014.12.015]
94. Klade CS, Wedemeyer H, Berg T, Hinrichsen H, Cholewinska G, Zeuzem S, Blum H, Buschle M, Jelovcan S, Buerger V, Tauber E, Frisch J, Manns MP. Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41. Gastroenterology 2008; 134: 1385-1395 [PMID: 18471515 DOI: 10.1053/j.gastro.2008.02.058]
95. Wedemeyer H, Schuller E, Schlaphoff V, Stauber RE, Wiegand J, Schiefke I, Firbas C, Jilma B, Thursz M, Zeuzem S, Hofmann WP, Hinrichsen H, Tauber E, Manns MP, Klade CS. Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C. Vaccine 2009; 27: 5142-5151 [PMID: 19559112 DOI: 10.1016/j.vaccine]
96. Frey SE, Houghton M, Coates S, Abrignani S, Chien D, Rosa D, Pileri P, Ray R, Di Bisceglie AM, Rinella P, Hill H, Wolff MC, Schultze V, Han JH, Scharschmidt B, Belshe RB. Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine 2010; 28: 6367-6373 [PMID: 20619382 DOI: 10.1016/j.vaccine.2010.06.084]
97. Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R, Brown A, Antrobus R, Ammendola V, Naddeo M, O'Hara G, Willberg C, Harrison A, Grazioli F, Esposito ML, Siani L, Traboni C, Oo Y, Adams D, Hill A, Colloca S, Nicosia A, Cortese R, Klenerman P. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med 2012; 4: 115ra1 [PMID: 22218690 DOI: 10.1126/scitranslmed.3003155]
98. Law JL, Chen C, Wong J, Hockman D, Santer DM, Frey SE, Belshe RB, Wakita T, Bukh J, Jones CT, Rice CM, Abrignani S, Tyrrell DL, Houghton M. A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans. PLoS One 2013; 8: e59776 [PMID: 23527266]
99. Habersetzer F, Honnet G, Bain C, Maynard-Muet M, Leroy V, Zarski JP, Feray C, Baumert TF, Bronowicki JP, Doffoël M, Trépo C, Agathon D, Toh ML, Baudin M, Bonnefoy JY, Limacher JM, Inchauspé G. A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C. Gastroenterology 2011; 141: 890-899.e1-4 [PMID: 21699798 DOI: 10.1053/j.gastro.2011.06.009]
100. Alvarez-Lajonchere L, Shoukry NH, Grá B, Amador-Cañizares Y, Helle F, Bédard N, Guerra I, Drouin C, Dubuisson J, González-Horta EE, Martínez G, Marante J, Cinza Z, Castellanos M, Dueñas-Carrera S. Immunogenicity of CIGB-230, a therapeutic DNA vaccine preparation, in HCV-chronically infected individuals in a Phase I clinical trial. J Viral Hepat 2009; 16: 156-167 [PMID: 19017255]
101. Thimme R, Binder M, Bartenschlager R. Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. FEMS Microbiol Rev 2012; 36: 663-683 [PMID: 22142141 DOI: 10.1111/j.1574-6976.2011.00319.x]
102. Gorzin Z, Gorzin AA, Tabarraei A, Behnampour N, Irani S, Ghaemi A. Immunogenicity evaluation of a DNA vaccine expressing the hepatitis C virus non-structural protein 2 gene in C57BL/6 mice. Iran Biomed J 2014; 18: 1-7 [PMID: 24375156]
103. Gokhale NS, Vazquez C, Horner SM. Hepatitis C Virus. Strategies to Evade Antiviral Responses. Future Virol 2014; 9: 1061-1075 [PMID: 25983854]
104. Wong MT, Chen SS. Emerging roles of interferon-stimulated genes in the innate immune response to hepatitis C virus infection. Cell Mol Immunol 2014; Epub ahead of print [PMID: 25544499 DOI: 10.1038/cmi.2014.1]